received 800 mg of IV ibuprofen administered over 5 to 10 minutes preoperatively. Vital signs, adverse events, and pain scores were assessed.
Findings: Approximately 22% (65 of 300) of patients reported adverse events (serious and nonserious). The most common adverse event was infusion site pain (34 of 300 [11%]). No deaths were reported. Nine subjects reported serious adverse events, 8 of which occurred during the first 6 hours. All serious events reported were judged unrelated to ibuprofen. Of the 300 total patients, 2 (0.67%) discontinued the study drug due to an adverse event (1 patient discontinued the study because of infusion site pain, and 1 patient withdrew due to a hypersensitivity reaction after drug administration).
Implications: Our study found that IV ibuprofen infused over 5 to 10 minutes at induction of anesthesia is a safe administration option for surgical patients. 
INTRODUCTION
Although the importance of controlling postoperative pain is widely accepted, achieving this goal remains a challenge. 1 The 2012 Updated Report by the American Society of Anesthesiologists Task Force on Acute Pain Management recommends a multimodal approach to pain management. 2 The task force agrees that, unless contraindicated, patients should receive an aroundthe-clock regimen of NSAIDs, cyclooxygenase-2 selective inhibitors, and/or acetaminophen. Following this guidance and using a multimodal approach, numerous randomized, double-blind, placebo-controlled trials were conducted in surgical patients undergoing orthopedic procedures evaluating both pain reduction and the opioid-sparing effects of intravenous (IV) ibuprofen. These studies demonstrated a significant reduction in pain and a morphine-sparing effect when IV ibuprofen therapy (each dose infused over 30 minutes) was initiated, either at induction of anesthesia or perioperatively. [3] [4] [5] Although the 30-minute infusion of IV ibuprofen has been shown to be safe and efficacious, further shortening of the infusion time may provide additional benefits. A 5-to 10-minute infusion of IV ibuprofen would significantly shorten the T max and time of onset of the therapeutic action compared with the 30-to 60-minute infusion protocol or peroral administration. It would then eliminate any variability in ibuprofen's pharmacodynamics associated with the variable absorption rate of the orally administered formulation of the drug. 6 These factors are particularly critical in the perioperative period, during which time and pain are closely related. Emergency medicine is another specialty in which rapid infusion of IV ibuprofen may prove beneficial.
A recent study in healthy subjects found that a shortened infusion time of 5 to 7 minutes for IV ibuprofen is well tolerated and results in a higher C max and shorter T max compared with a 30-minute infusion or oral administration. 7 Subsequently, a Phase IV, multicenter, open-label, surveillance safety study found that a shortened infusion time of IV ibuprofen can be safely administered in hospitalized patients experiencing fever or mild to moderate or moderate to severe pain. 8 The present trial was designed to further evaluate the safety of a shortened infusion time of IV ibuprofen in surgical patients. We hypothesized that a shortened infusion time in surgical patients would present no additional risks compared with a 30-minute infusion period.
PATIENTS AND METHODS
This Phase IV, multicenter, open-label, clinical surveillance study was designed to assess the safety of IV ibuprofen administered over 5 to 10 minutes to hospitalized adult patients undergoing surgical procedures. The study was approved by site-specific institutional review boards. Adults (ie, aged Z18 years) scheduled for surgery and with an anticipated need for postoperative analgesia were eligible for study inclusion. Exclusion criteria included: inadequate IV access (ie, difficulties in securing reliable IV access by using a Z20-gauge diameter catheter); history of allergy or hypersensitivity to any component of IV ibuprofen or aspirin (or related products); or any active, clinically significant bleeding. Patients were excluded from enrollment if they had taken NSAIDs o6 hours before IV ibuprofen administration; also excluded were pregnant or breastfeeding female patients or patients in the perioperative period of coronary artery bypass graft surgery.
Eligible patients received up to 4 doses of 800 mg of IV ibuprofen, administered at 6-hour intervals, depending on patient requirements. The first dose of IV ibuprofen was administered before the surgical procedure, approximately at the time of induction of anesthesia. The drug was diluted in saline and administered at a concentration of r4 mg/mL over 5 to 10 minutes. The use of the 800-mg preoperative dose of IV ibuprofen was based on the product package insert and previous surgical studies. [3] [4] [5] 9 All NSAIDs (excluding ibuprofen) were restricted during the treatment and posttreatment periods. There was no formal anesthesia protocol.
Assessments
To evaluate the safety of a single dose of IV ibuprofen administered over 5 to 10 minutes for the treatment of postoperative pain, vital signs were recorded at baseline and 4 hours after the initial IV ibuprofen infusion. The incidence of adverse events T.J. Gan et al.
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occurring over the 6 hours after administration of IV ibuprofen was recorded. In addition, each site investigator assessed the association between any adverse event and IV ibuprofen.
To evaluate the safety of multiple doses of IV ibuprofen administered over 5 to 10 minutes for the treatment of postoperative pain, the incidence of adverse events occurring within the 6 hours after administration of the last dose of IV ibuprofen was collected.
Pain intensity was measured over the subsequent 6 hours after the initial drug infusion. No comparative analysis of IV ibuprofen versus the standardized pain management was conducted. In this multicenter, openlabel, clinical surveillance study, visual analog scale (VAS) scores were assessed to verify adequate pain relief comparable to published reports in the literature. Pain intensity was quantified based on patients' self-assessment, performed by using a 0-to 100-mm VAS (0 mm indicating no pain and 100 mm indicating intense pain).
Statistical Analysis
Formal sample size calculations were not performed, nor were formal statistical tests applied to assess the differences before and after the drug infusion. The intent of the present study was to enroll patients to provide descriptive safety and efficacy data on perioperative rapid infusions of IV ibuprofen. Considering this design and the realistic assessment of patient numbers that could be recruited in such a multicenter study, the overall number of 300 patients was considered adequate for safety assessment of a shortened IV ibuprofen infusion as well as monitoring of the dynamics of pain severity during the study period.
Continuous data were summarized in tables listing means and SDs. When appropriate, the data are presented as absolute numbers and percentages relative to the overall number of patients. Categorical data are summarized by using absolute numbers and percentages. The descriptive statistical analysis was conducted by using SAS version 9.1.3 (SAS Institute, Inc, Cary, North Carolina).
RESULTS
Twenty-one clinical centers in the United States enrolled patients (Table I) . A total of 300 surgical patients were enrolled in the study; their mean age was 51 (13.4) years. Demographic characteristics are presented in Table II . Of the 300 enrolled patients, 252 (84%) received a single dose of IV ibuprofen administered before the surgical procedure, and 48 (16%) patients received Z2 doses (preprocedure and postprocedure) ( Table III) . From the 300 patients enrolled, the most common surgical procedures included hernia repair, n ¼ 41 (14%); hysterectomy, n ¼ 40 (13%); and cholecystectomy, n ¼ 29 (10%) ( Table IV) .
No significant differences in vital signs were observed between the preanesthesia period and 4 hours' postsurgery ( Table V) . Adverse events were reported for 65 (22%) of the 300 patients. Of the 65 patients experiencing adverse events, most events were mild to moderate in intensity (57 of 65 [88%]). Of the 252 patients who received a single dose of IV ibuprofen administered before the surgical procedures, 49 (19%) experienced an adverse event within 6 hours of ibuprofen administration. Of the 48 patients who received IV ibuprofen both presurgery and postsurgery, 16 (33%) experienced an adverse event within 6 hours after the last dose of IV ibuprofen ( Table VI) .
The most common adverse event experienced by patients was pain or discomfort at the infusion site (42 of 300 [14%]). Other adverse events reported by 43% of patients included nausea, flatulence, anemia, and bradycardia (Table VII) . Excluding infusion site reactions, most adverse events were considered unrelated to IV ibuprofen in the opinion of the investigator. Bradycardia events were categorized as not related to IV ibuprofen in the opinion of the investigator. Nine serious adverse events were reported. Serious events and the investigator's assessment of relationship to IV ibuprofen are presented in Table VIII .
Two (0.67%) of the 300 patients discontinued the study drug due to an adverse event. One patient discontinued study drug due to infusion site pain, and 1 patient withdrew from the study due to a systemic hypersensitivity reaction.
Pain scores were collected during the postoperative period. The postoperative analgesia regimen was not controlled, allowing study sites to follow their standard postoperative pain management protocol. In the 6 hours after drug administration, mean VAS scores ranged from 26.3 to 33.4 mm. The mean (SD) values of the VAS for each time point are depicted in the Figure. 
DISCUSSION
Treatment of postoperative pain continues to be a challenge. Ibuprofen effectively reduces pain and inflammation by reducing prostaglandin synthesis. 10 An IV formulation of ibuprofen has the potential to quickly reduce postoperative pain by arresting the inflammatory cascade caused by surgical procedures. In a previous multicenter, randomized, placebo-controlled trial conducted in orthopedic surgical patients, pain reduction and the opioid-sparing effect of IV ibuprofen were evaluated as part of multimodal postoperative pain management in which the first dose of 800 mg IV ibuprofen was administered before the surgical procedure and therapy was continued for at least 24 hours (doses administered every 6 hours). 3 The study showed that IV ibuprofen provided a significant reduction (430%) in both pain intensity and narcotic use in surgical patients in the postoperative period.
Although the current prescribing information recommends that the infusion time for IV ibuprofen be T.J. Gan et al.
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no less than 30 minutes, a healthy volunteer trial was conducted to evaluate the pharmacokinetics and safety of equivalent single doses of 800-mg IV ibuprofen (administered over 5-7 minutes) and 800-mg oral ibuprofen. 7 The study showed that IV ibuprofen had bioavailability equivalent to oral ibuprofen, but the mean C max of IV ibuprofen was approximately twice that of the oral dose. The median T max of the IV infusion administered over 5 to 6 minutes was 6.5 minutes compared with 1.50 hours for the oral dose.
No safety concerns were noted with the rapid infusion time in these healthy volunteers. It would be beneficial to plan a study comparing the pharmacokinetic profile, clinical effects, and incidence of the adverse reactions between the 2 modes of IV ibuprofen administration: 5-to 10-minute versus a 30-minute infusion. In the present study, 22% of patients (65 of 300) who received rapid IV ibuprofen infusions experienced adverse events, and the most common adverse event was infusion site reaction. The incidence of adverse effects was higher in patients receiving multiple infusions of ibuprofen. Because the majority of the adverse events were related to infusion site reactions, it is reasonable to expect a correlation between the incidence of such events and the frequency of drug administration. Another possible explanation is that patients requiring repeated doses of ibuprofen were sicker and more prone to adverse reactions. The infusion site pain safety results from the present study are consistent with other IV analgesic infusion pain safety data. Previous IV analgesic studies have reported a 5% to 29% incidence of infusion site pain, [11] [12] [13] and propofol has exhibited up to a 60% incidence.
14 Injection site pain ranging from 19% to 29% was reported with ketorolac, another injectable NSAID.
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In previous studies of IV ibuprofen in surgical patients, 4, 5, 9 up to 90% of patients experienced an adverse event; all patients received concomitant morphine during these studies; adverse events were collected regardless of investigator assessment of relationship to IV ibuprofen. Previous studies and data collected in this trial suggest that a more rapid infusion of IV ibuprofen does not pose a safety risk to patients. All NSAIDS contain label warnings and precautions regarding the risk of gastrointestinal bleeding or ulceration, cardiovascular risks, renal and hepatic injury, and bleeding related to platelet dysfunction. However, these treatment-related complications are predominantly associated with long-term drug use, whereas acute perioperative use of NSAIDs is considered relatively safe. Previous studies with IV ibuprofen have not demonstrated any increased risk of serious adverse events. [3] [4] [5] Moreover, no cases of perioperative bleeding, cardiovascular and hepatorenal complications, or gastrointestinal ulceration were observed. These data are consistent with a recently published meta-analysis examining the safety of NSAIDs, which demonstrated no short-term serious gastrointestinal outcomes such as bleeding or perforation. 15 Longterm studies showed an association between NSAID intake and occurrence of serious adverse events. However, ibuprofen consistently had been at the lower end of toxicity rankings, whereas ketorolac and azapropazone demonstrate a higher risk. 16 The study found that the risk of bleeding was increased with advancing age, presence of arterial hypertension, history of bleeding, and use of anticoagulant agents. The present trial was 1 of 2 Phase IV, open-label studies conducted to investigate the safety of a shortened infusion time of IV ibuprofen. A complementary study (Part 1 of the study) in hospitalized patients with existing pain and fever found that treatment with IV ibuprofen resulted in adverse events in 43 (29%) of the 150 patients. 8 According to study results, the most common adverse event experienced by patients was pain at the infusion site ( determined by the investigator to be related to ibuprofen therapy. No incidence of bleeding, cardiovascular events, renal and/or hepatic injury, gastrointestinal bleeding, or ulceration were reported in either study.
Mean postoperative VAS scores ranged from 26.3 to 33.4 mm. The pain scores were consistent with a postoperative study that also initiated IV ibuprofen therapy before surgery, 3 suggesting that postoperative pain was well managed. The data support the hypothesis that IV ibuprofen is a useful baseline agent in multimodal pain control management in the perioperative setting.
The study had several limitations. As an open-label, single-arm study, no control group was included. In addition, the renal function before and after surgery was not directly compared in this study. Furthermore, the type of surgical procedure, anesthesia protocol, and protocol-defined pain regimen was not controlled. Although there was an absence of consistency between surgeries, the variability allowed for a broader assessment of the safety and utility of IV ibuprofen used in diverse surgical settings with multiple analgesic protocols.
CONCLUSIONS
The results of this trial continue to support a body of evidence establishing that a 5-to 10-minute infusion of IV ibuprofen can be safely and effectively administered in a wide variety of surgical patients experiencing mild, moderate, or severe pain. Furthermore, these results support the safe use of IV ibuprofen as a baseline therapy in a multimodal analgesic regimen. A shortened infusion can easily be integrated into the preoperative analgesia regimen in which IV access has already been established, decreasing the health provider's time spent on administration and thus reducing the burden on the operating room personnel. Figure. Postoperative pain intensity. Mean pain intensity as measured by using visual analog scale (VAS) scores from time 0 to 360 minutes for patients administered a single 800-mg dose of intravenous ibuprofen before the surgical procedure. Postoperative analgesia was not controlled. The VAS used a 100-mm scale.
